LINAGLIPTIN

Post-LOESM

linagliptin

ANDAORALTABLET
Approved
Aug 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Dipeptidyl Peptidase 4 Inhibitors

Pharmacologic Class:

Dipeptidyl Peptidase 4 Inhibitor

Clinical Trials (5)

NCT04180813N/ATerminated

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Started Mar 2020
85 enrolled
Diabetes Mellitus, Type 2
NCT03629054Phase 1Completed

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Started Aug 2018
30 enrolled
Healthy
NCT03429543Phase 3Completed

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Started Mar 2018
175 enrolled
Diabetes Mellitus, Type 2
NCT03338803N/ACompleted

Real World Glycemic Effectiveness of Linagliptin

Started Nov 2017
11,001 enrolled
Diabetes Mellitus, Type 2
NCT03259490Phase 1Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Started Aug 2017
30 enrolled
Healthy